 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: TIGECYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mID[0m[31m=[0m[31m"t11"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><caption [0m[31mID[0m[31m=[0m[31m"G27e24559[0m[31m-6ed6-49f7-a922-9571f94945ca"[0m[31m>Table [0m[1;31m10[0m[31m. Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mcaption[0m[31m><colgroup><col [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><[0m[31m/[0m[31mcolgroup[0m[31m><thead><tr><th/><th>Tigecycline for injection<[0m[31m/[0m[31mth[0m[31m><th>Levofloxacin<[0m[31m/[0m[31mth[0m[31m><th/><[0m[31m/[0m[31mtr[0m[31m><tr><th/><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m95[0m[31m% [0m
[31mCI<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tfoot><tr><td [0m[31mcolspan[0m[31m=[0m[31m"4"[0m[31m><sup>a<[0m[31m/[0m[31msup[0m[31m TIGECYCLINE: clinical_studies_table: > Patients at higher risk of death include patients with any one of the following: [0m
[31m&#x2265;[0m[1;31m50[0m[31m year of age; PSI score &#x2265;[0m[1;31m3[0m[31m; or bacteremia due to <content [0m[31mstyleCode[0m[31m=[0m[31m"italics"[0m[31m>Streptococcus pneumoniae<[0m[31m/[0m[31mcontent[0m[31m><paragraph><sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m95[0m[31m% confidence interval for the treatment [0m
[31mdifference<[0m[31m/[0m[31mparagraph[0m[31m><paragraph><sup>c<[0m[31m/[0m[31msup[0m[31m> After at least [0m[1;31m3[0m[31m days of intravenous therapy, a switch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtfoot[0m[31m><tbody><tr><td>Study [0m[1;31m1[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-20.8[0m[31m, [0m[1;31m7[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m7[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td>Study [0m[1;31m2[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: recent_major_changes: RECENT MAJOR CHANGES SECTION Dosage and Administration, Monitoring of Blood Coagulation Parameters [0m[1;31m([0m[1;31m2.4[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m2020[0m[31m Warnings and Precautions, Monitoring of [0m
[31mBlood Coagulation Parameters [0m[1;31m([0m[1;31m5.6[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m2020[0m[31m Warnings and Precautions, Tooth Discoloration and Enamel Hypoplasia [0m[1;31m([0m[1;31m5.7[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m/[0m[1;31m2020[0m[31m Warnings and Precautions, Inhibition of Bone Growth [0m[1;31m([0m[1;31m5[0m[31m. TIGECYCLINE: [0m
[31mrecent_major_changes: [0m[1;31m8[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m/[0m[1;31m2020[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: package_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Risk Summary Tigecycline for injection, like other tetracycline class antibacterial drugs, may cause permanent discoloration of deciduous teeth and [0m
[31mreversible inhibition of bone growth when administered during the second and third trimesters of pregnancy [0m[31m . There are no available data on the risk of major birth defects or miscarriage following [0m
[31mthe use of tigecycline for injection during pregnancy. Administration of intravenous tigecycline in pregnant rats and rabbits during the period of organogenesis was associated with reduction in fetal [0m
[31mweights and an increased incidence of skeletal anomalies [0m[1;31m([0m[31mdelays in bone ossification[0m[1;31m)[0m[31m at exposures of [0m[1;31m5[0m[31m and [0m[1;31m1[0m[31m times the human exposure at the recommended clinical dose in rats and rabbits, [0m
[31mrespectively. TIGECYCLINE: pregnancy: Advise the patient of the potential risk to the fetus if tigecycline for injection is used during the second or third trimester. The estimated background risk of [0m
[31mmajor birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U. S. general population, [0m
[31mthe estimated background risk in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. Data Human Data The use of tetracycline-class antibacterial drugs, that includes tigecycline [0m
[31mfor injection, during tooth development [0m[1;31m([0m[31msecond and third trimester of pregnancy[0m[1;31m)[0m[31m may cause permanent discoloration of deciduous teeth. This adverse reaction is more common during long-term use of [0m
[31mtetracyclines but has been observed following repeated short-term courses. Tigecycline for injection may cause reversible inhibition of bone growth when administered during the second and third [0m
[31mtrimesters of pregnancy. TIGECYCLINE: pregnancy: A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of [0m[1;31m25[0m[31m mg/kg every [0m[1;31m6[0m[31m hours. Animal Data In [0m
[31membryo-fetal development studies, tigecycline was administered during the period of organogenesis at doses up to [0m[1;31m12[0m[31m mg/kg/day in rats and [0m[1;31m4[0m[31m mg/kg in rabbits or [0m[1;31m5[0m[31m and [0m[1;31m1[0m[31m times the systemic exposure at [0m
[31mthe recommended clinical dose, respectively. In the rat study, decreased fetal weight and fetal skeletal variations [0m[1;31m([0m[31mreduced ossification of the pubic, ischial, and supraoccipital bones and increased [0m
[31mincidences of rudimentary [0m[1;31m14[0m[31m th rib[0m[1;31m)[0m[31m were observed in the presence of maternal toxicity at [0m[1;31m12[0m[31m mg/kg/day [0m[1;31m([0m[1;31m5[0m[31m times the recommended clinical dose based on systemic exposure[0m[1;31m)[0m[31m. In rabbits, decreased fetal [0m
[31mweights were observed in the presence of maternal toxicity at [0m[1;31m4[0m[31m mg/kg [0m[1;31m([0m[31mequivalent to the human exposure at the recommended clinical dose[0m[1;31m)[0m[31m. TIGECYCLINE: pregnancy: In preclinical safety studies, [0m[1;31m14[0m[31m [0m
[31mC-labeled tigecycline crossed the placenta and was found in fetal tissues.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: product_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: pharm_class_cs         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: clinical_studies: [0m[1;31m3[0m[1;31m)[0m[31m Legionella pneumophila [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m Streptococcus pneumoniae [0m[1;31m([0m[31mpenicillin-susceptible only[0m[1;31m)[0m[31m b [0m[1;31m44[0m[31m/[0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m95.7[0m[1;31m)[0m[31m [0m[1;31m39[0m[31m/[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m88.6[0m[1;31m)[0m[31m To further evaluate the [0m
[31mtreatment effect of tigecycline, a post-hoc analysis was conducted in CABP patients with a higher risk of mortality, for whom the treatment effect of antibacterial drugs is supported by historical [0m
[31mevidence. The higher-risk group included CABP patients from the two studies with any of the following factors: Age ≥[0m[1;31m50[0m[31m years PSI score ≥[0m[1;31m3[0m[31m Streptococcus pneumoniae bacteremia The results of this [0m
[31manalysis are shown in Table [0m[1;31m10[0m[31m. Age ≥[0m[1;31m50[0m[31m was the most common risk factor in the higher-risk group. Table [0m[1;31m10[0m[31m. TIGECYCLINE: clinical_studies: Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality a Tigecycline for injection Levofloxacin n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m95[0m[31m% CI b a Patients at higher risk of death include patients with any one of [0m
[31mthe following: ≥[0m[1;31m50[0m[31m year of age; PSI score ≥[0m[1;31m3[0m[31m; or bacteremia due to Streptococcus pneumoniae b [0m[1;31m95[0m[31m% confidence interval for the treatment difference c After at least [0m[1;31m3[0m[31m days of intravenous therapy, a [0m
[31mswitch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. Study [0m[1;31m1[0m[31m c CE Higher risk Yes [0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82.4[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m No [0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-20.8[0m[31m, [0m
[1;31m7[0m[31m. TIGECYCLINE: clinical_studies: [0m[1;31m1[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m [0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m No [0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77.6[0m[1;31m)[0m[31m [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8.7[0m[1;31m)[0m[31m Study [0m[1;31m2[0m[31m CE Higher risk Yes [0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88.8[0m[1;31m)[0m[31m [0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m [0m
[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m No [0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m [0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8.6[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m [0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m No [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThank you for confirming. I will now proceed with the next step to find the information.[0m

[32mPlease provide me with some relevant text, and I will use the `relevant_extracts` tool/function-call for this purpose. If the question asks for information about a specific drug, make sure to begin by[0m
[32mincluding that drug in the `filter_drugs` field. If you say DO-NOT-KNOW, it means you found no relevant docs, and I can try the next step, using a web search.[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mDocumentHandler[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m                Try a web search using the `relevant_search_extracts` tool,[0m
[31m                to see if it can help answer the question.[0m
[31m                [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does TIGECYCLINE increase or decrease the risk of [0m
[31mhip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mI have initiated a query with FDAHandler to determine if TIGECYCLINE [0m
[32mincreases or decreases the risk of hip fracture. However, I have not yet received a response that would provide the necessary information to answer your question. Without specific data from the FDA [0m
[32mlabel, I cannot provide a reliable answer. Therefore, my response at this time must be DO-NOT-KNOW. Once I receive the relevant information, I will be able to provide a more definitive answer.[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I sent a query to FDAHandler to determine if TIGECYCLINE has any impact on the risk of hip fracture."[0m[32m,[0m
[32m      [0m[32m"I have not yet received a response from FDAHandler, which is necessary to provide a reliable answer."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does TIGECYCLINE increase or decrease the risk of hip fracture?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I sent a query to FDAHandler to determine if TIGECYCLINE has any impact on the risk of hip fracture."[0m[34m,[0m
[34m      [0m[34m"I have not yet received a response from FDAHandler, which is necessary to provide a reliable answer."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does TIGECYCLINE increase or decrease the risk of hip fracture?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I sent a query to FDAHandler to determine if TIGECYCLINE has any impact on the risk of hip fracture.[0m
[1;31m2[0m[31m. I have not yet received a response from FDAHandler, which is necessary to provide a reliable answer.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe question was whether TIGECYCLINE increases or decreases the risk of hip fracture. I sent a query to FDAHandler to obtain information on this matter, but I have not received a response that would [0m
[32mprovide the necessary data to answer the question. Without specific information from the FDA label, I cannot provide a reliable answer. Therefore, the final answer is DO-NOT-KNOW.[0m
